N/A N=45 Scleroderma ARFI Imaging of the Skin
Scleroderma
Primary: Mean Skin Stiffness — 2.68; 2.07; 2.23; 2.27 meters per second — p=0.005
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=151 Systemic Lupus Erythematous and Heart Conduction Disorders
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
Phase 2 N=142 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
Phase 2 N=10 A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Scleroderma, Diffuse · Scleroderma, Systemic
Primary: Change in Modified Rodnan Skin Score — -8.6; -2.3 MRSS score
N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
Phase 2 N=19 IL1-TRAP, Rilonacept, in Systemic Sclerosis
Scleroderma · Systemic Sclerosis · Diffuse Scleroderma
Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score
Phase 2 N=12 Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
Phase 2 N=20 Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Systemic Sclerosis
Primary: Change in Modified Rodnan Skin Score (MRSS) — -10; -3.0 units on a scale
N/A N=31 Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus
Primary: Percentage of Subjects Who Correctly Answered a Knowledge Assessment Item Immediately Before and After an Educational Lecture — 52; 94; 19; 90 percentage of participants
Phase 2 N=97 Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Systemic Sclerosis
Primary: Change From Baseline in Modified Rodnan Skin Score to Week 24 — -2.45; -4.76 score on a scale — p=0.0291
Phase 4 N=7 Predicting Inflammatory Skin Disease Response to IL-23 Blockade
Psoriasis Vulgaris
Primary: Psoriasis Area and Severity Index (PASI) Score — 3.9 score on a scale
Phase 2 N=19 Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
SYSTEMIC SCLERODERMA
Primary: Time to Treatment Failure — 0; 8 participants
Phase 3 N=6 High Dose Cyclophosphamide for Treatment of Scleroderma
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Phase 2 N=18 Anakinra for Inflammatory Pustular Skin Diseases
Sneddon-Wilkinson · Acrodermatitis Continua of Hallopeau · Pustular Psoriasis
Primary: Number of Participants Treated With Anakinra Who Achieve 50% Disease Improvement by the End of Week 12, as Measured by Total Body Surface Area Involvement (TBSAI50) — 7…
N/A N=15 Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Systemic Sclerosis · Scleroderma
Primary: The Benefit That an Antifibrotic Agent and Ambrisentan Combination Have on the Cutaneous Involvement of Patients With Early Diffuse Systemic Sclerosis by Utilizing the…
Phase 2 N=9 Imatinib in Systemic Sclerosis
Scleroderma, Systemic
Primary: Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline — -32 percentage of change in MRSS — p=0.005
N/A N=135 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions
Drug Hypersensitivity
Primary: Skin Healing Time — 13.75; 19; 40.5; 34 days — p=0.01
Phase 2 N=8 Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis
Dermatomyositis, Adult Type
Primary: The Primary Endpoint Analysis Would be Overall Response Rate Measured by the Number of Participants Experiencing at Least 4 Points Decrease in CDASI Activity Score at 3…
Phase 3 N=158 Scleroderma Lung Disease
Lung Diseases · Pulmonary Fibrosis · Systemic Scleroderma
Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted
N/A N=125 Families-At-risk for Interstitial Lung Disease Study
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants
Phase 2 N=264 Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus · Active Cutaneous Lupus Erythematosus
Primary: Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 — -12.7; -9.0; -13.0; -14.5 joints — p=0.037
Phase 2 N=47 Tofacitinib for Immune Skin Conditions in Down Syndrome
Down Syndrome · Alopecia Areata · Atopic Dermatitis / Eczema
Primary: Number of Serious Adverse Events (SAE) Definitely Related to Tofacitinib Treatment. — 0 Serious Adverse Events
Phase 2 N=12 Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients
Discoid Lupus Erythematosus
Primary: Cutaneous LE Diseases Area and Severity Index (CLASI) Score Based on Extent of Symptoms
Phase 2 N=75 A Study In Adults With Moderate To Severe Dermatomyositis
Dermatomyositis
Primary: Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) — -3.44…
Phase 2 N=15 Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Systemic Sclerosis · Scleroderma
Primary: Number of Participants Who Experience Grade 3 or Higher Adverse Events That Occur at or Before Week 24 — 0; 0 Participants
Phase 2 N=88 A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Primary: Proportion of Participants With at Least One Adverse Events (AEs) or Serious AEs (SAEs) in 1 Year — 35; 40 Participants
N/A N=267 Taking Charge of Systemic Sclerosis
Scleroderma
Primary: Change in Managing Symptoms Scale on the PROMIS® Self-efficacy Short Form 8 — 0.35; 0.94; 0.50; 1.49 units on a scale — p=0.87
Phase 1 N=7 Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
Cutaneous Lupus
Primary: Change in Percentage of UVB-induced Apoptotic Epidermal Cells — 20.06; 3.03; -17.03 percentage of epidermal cells
Phase 2 N=20 Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease
Sclerotic Graft Versus Host Disease · Imatinib Mesylate
Primary: Percent Change in Absolute Range of Motion (ROM) From Baseline to 6 Months — 94; 35; 16; 21 Percent change from baseline
Phase 2 N=76 Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Primary: The ACR CRISS Composite Score (0-1) at Week 52 — 0.8537; 0.8502 scores on ascale